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ABSTRACT
PROMOTING DIFFERENTIATION AND SURVIVAL OF HUMAN C-KIT+
CARDIAC PROGENITOR CELLS EX VIVO
Tareq Al-Maqtari
June 8, 2015

c-kit+ cardiac progenitor cells (CPCs) have recently gained much attention
due to the therapeutic effects they exert on cardiac function following their
administration into the infarcted heart as evidenced by animal studies and by a
recent clinical trial (SCIPIO). However, injecting these cells in the heart is
associated with poor differentiation into specialized cardiac cell types and with
rapid death of the engrafted cells. With the ultimate goal of advancing cardiac
stem cell therapy, we sought to facilitate the differentiation of human CPCs into
cardiac cell types (e.g. cardiomyocytes, smooth muscle cells, endothelial cells
and cardiac fibroblasts) by overexpressing selected cardiac transcription factors
in vitro. To achieve that, Gata4, MEF2C, NKX2.5 and TBX5, were overexpressed
in CPCs via lentivirus. When individually overexpressed, Gata4 upregulated
some cardiomyocyte, smooth muscle cell, and fibroblast markers. TBX5,
however,

induced

only

few

cardiomyocyte

markers,

indicating

partial

differentiation. In addition, these changes in CPC cardiac gene expression
observed

with

Gata4

overexpression
v

were

accompanied

by

marked

morphological changes, manifested by the cells becoming wider and largely
polygonal. However, introducing the aforementioned transcription factors in
various combinations largely failed to further enhance the cardiac differentiation
of CPCs induced by Gata4 or TBX5, underscoring the complexity of the
interaction between the cardiac transcription factors. Likewise, addition of the
chromatin remodeling transcription factor BAF60C to Gata4 and/or TBX5 did not
further potentiate their pro-differentiation effects in CPCs.
In addition to inducing differentiation, we also endeavored to promote CPC
survival by overexpressing a pro-survival gene. To that end, a constitutively
active mutant form of Nrf2 (caNrf2) was overexpressed in CPCs. caNrf2
overexpression protected CPCs against hydrogen peroxide- and 2, 3-dimethoxy1, 4-naphthoquinone (DMNQ)-induced oxidative stress in vitro without altering
the overall growth characteristics of the cells. Taken together, our results
highlight the potential of Gata4 in facilitating differentiation and the protective role
of caNrf2 in CPCs. These effects of Gata4 and caNrf2 may enhance the
regenerative capabilities of CPCs and could thus be utilized to advance cellbased heart therapies.
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CHAPTER I
INTRODUCTION

Discovery of c-kit+ cardiac progenitor cells in the adult human heart
Myocardial infarction (MI) is a main cause of mortality and morbidity
worldwide. In the USA, MI is responsible for approximately 50% of all
cardiovascular deaths [1]. MI often occurs when an atherosclerotic plaque
ruptures into a coronary artery, which may occlude the artery, and cause
necrosis in the infarcted area [2]. Following infarction, both infarcted and noninfarcted regions of the heart undergo a remodeling process, causing the
infarcted region to lose contractility. Eventually, the infarct region heals leaving a
fibrotic non-contractile tissue which culminates in heart failure [3]. Although
reperfusion and pharmacological interventions for acute MI patients have been
successful in lowering mortality, they fall short in repairing the damaged cardiac
tissue [4], underscoring the need for newer therapeutic approaches.
The long-standing notion of the heart being a terminally-differentiated
organ has been challenged by cardiomyocyte-renewal findings in a number of
studies [5-8]. The innate self-regenerative potential of the heart has been
supported by the discovery of resident cardiac lin-/c-kit+ cardiac progenitor cells
(CPCs) with stem cell characteristics (e.g. clonogenicity, self-renewal, and
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multipotency) [9]. These CPCs have been isolated from multiple mammalian
species including rats, pigs, dogs and humans [10-13]. The presence of CPCs
that are positive for both the stem cell marker c-kit and one or more early cardiac
cell markers (e.g. GATA4, MEF2C and ETS1) suggests that CPCs are capable of
differentiating into committed cardiac cell types [13]. Indeed, the ability of c-kit+
CPCs present in embryonic hearts to generate specialized cardiac cell types
including cardiomyocytes, smooth muscle cells and endothelial cells during
cardiogenesis have been shown [14, 15]. Currently, however, a debate is rising
in regards to whether these c-kit+ cells are bona fide cardiac stem cells or
stromal cells that reside in the heart and can generate cardiac lineages under
certain conditions [16]. Thus, different authors may have different names for
these cells including: c-kit+ cardiac stem cells, CPCs and cardiac stromal cells.
However, For the purpose of this work, these cells will be referred to as “cardiac
progenitor cells or CPCs”.

CPC therapy for ischemic cardiomyopathy following MI
The intriguing properties of CPCs and the need for a treatment that can
replace the infarcted portion of the myocardium with a functional viable tissue
have led numerous groups to assess the therapeutic potential of these cells.
Indeed, independent laboratories have shown promising findings in animal
models. For instance, c-kit+ cells isolated from adult Fischer rats exhibited stem
cell properties and appeared to give rise in vitro and in vivo to at least 3 cell types
within the cardiac tissue, namely cardiomyocytes, smooth muscle cells and
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endothelial cells [9]. When injected in two loci bordering the infarct region in a rat
model of MI, CPCs appeared to generate small cardiomyocytes and new blood
vessels, thereby promoting functional recovery [9]. In addition, Tang et al. have
shown that intracoronary injection of CPCs one month after the induction of MI in
rats, decreased fibrosis, increased the viable tissues in the risk region, and
improved cardiac ejection fraction, a marker of cardiac function [17]. In a third
study, MI was induced in a porcine model by a 90-minute coronary occlusion
followed by reperfusion [18]. Three months later, autologous CPCs were injected
into the coronary artery using a balloon catheter and the analysis at one month
post-treatment showed that CPC-injected animals had improved cardiac function
as shown by greater ejection fraction and lower left ventricular end-diastolic
pressure, corroborating the therapeutic potential of CPCs.
These encouraging results in animal models led to the initiation of a phase
I

clinical trial [Cardiac

stem

cell infusion

in

patients with

ischemic

cardiomyopathy (SCIPIO)] in 2009. Albeit designed primarily to establish safety,
SCIPIO has corroborated the positive therapeutic outcomes of the intracoronary
infusion of CPCs as evidenced by improved left ventricular ejection fraction and
smaller infarct size [19]. In this trial, 1.0 x 106 autologous CPCs were injected into
16 patients via the intracoronary route 4 months after coronary artery bypass
grafting. When left ventricular ejection fraction was assessed 4 months after CPC
infusion, there was a significant improvement (increasing from 30.3% before
CPC infusion to 38.5%) while the control group exhibited no change. Also, twelve
months post treatment, ejection fraction further improved by an additional 4%,
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indicating a long-term beneficial effect. Moreover, infarct size, as assessed by
cardiac magnetic resonance imaging (MRI), decreased by 24% at 4 months and
by 30% at 12 months [20]. These positive effects on heart function were
accompanied by an improvement in the overall quality of life as shown by the
Minnesota Living with Heart Failure Questionnaire (MLHFQ).
Despite all the previous data that show the therapeutic potential of CPC
for heart repair after MI, some studies have shown multiple shortcomings with the
use of CPCs, including poor survival of the transplanted cells as well as lack of
differentiation into mature cardiomyocytes [11, 17, 21, 22] (See below for more
details). Addressing these issues may enhance the beneficial effects of CPCs for
heart repair.

CPCs do not differentiate upon injection in the infarcted heart
The main underlying cause of heart failure following MI is the loss of viable
contractile tissue [3] which is comprised of cardiomyocytes, smooth muscle cells
and endothelial cells. Thus, it is conceivable that injecting cells that can generate
functional cardiac cell types may be more conducive to heart recovery, conferring
CPCs a critical advantage since they are considered, by many, as the
progenitors of cardiomyocytes, endothelial cells and smooth muscle cells.
However, only marginal differentiation of CPCs was noted upon intracoronary
injection in a rat model of MI [17]. Indeed, although some injected cells
coexpressed few cardiomyocyte-specific proteins, the cells were rather small and
did not phenotypically resemble mature cardiomyocytes. In another study in
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mice, GFP-labeled CPCs were traced following infusion via the intramyocardial
and intracoronary routes [11] and their differentiation was assessed by
expression of both GFP and the cardiomyocyte marker α-sarcomeric actin.
Again, although few GFP-labeled cells co-expressed α-sarcomeric actin at 39
days post implantation, these cells did not exhibit identifiable sarcomeric
structures

and

their sizes

were

much

smaller than

the endogenous

cardiomyocytes. These studies constitute strong evidence that the injected CPCs
do not spontaneously give rise to functional cardiac cell types upon introduction
into the heart. That lack of differentiation into functional cardiac lineages is
thought to limit the therapeutic potential of CPCs in repairing the injured
myocardium.
Previous reports have demonstrated that multiple cell types can be
directed to differentiate, at least partially, into cardiac cell lineages via
introduction of cardiac transcription factors (TFs). For instance, cardiac TFs
Gata4, Tbx5, and a subunit of the BAF chromatin-remodeling complex, Baf60c,
directed ectopic differentiation of mouse mesoderm into beating cardiomyocytes
[23]. Another combination of cardiac TFs (GATA4, TBX5, NKX2.5, and BAF60C)
was sufficient to direct the differentiation of human embryonic stem cells into
cardiomyocytes [24]. Also, both human embryonic stem cells and induced
pluripotent stem cells generated cardiomyocyte-like cells following a plasmidbased transient overexpression of GATA4, BAF60C and the early cardiomyocyte
marker MESP1 [25]. Even fibroblasts (cardiac and dermal) were reprogrammed
into becoming functional cardiomyocyte-like cells in vitro and in vivo by
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overexpressing Gata4, Mef2c, and Tbx5 [26]. However, these findings were
challenged by a recent study [27], which could be ascribed to differences in
reagents or methodology.
In addition, several reports have shown that cells which express higher
levels of cardiac TFs (i.e. more cardiopoietic) exert superior therapeutic benefit
for the infarcted heart. For instance, mesenchymal stem cells (MSCs) expressing
Gata4 and Nkx2.5 (MSCs-GC) were superior to the naïve counterparts in
promoting cardiac recovery after MI, in a mouse model [28]. Indeed, introducing
MSCs-GC into the heart resulted in improved ejection fraction and fractional
shortening, and led eventually to a thicker ventricular wall. In another study, a
cocktail of TGF-β, activin, bone morphogenetic protein 4 (BMP4), retinoic acid,
insulin-like growth factor-1 (IGF-1), alpha-thrombin, and interleukin-6 (IL-6)
induced human MSCs to upregulate cardiac TFs [29]. These conditioned MSCs,
which express higher levels of cardiac TFs, were superior to the naïve
counterparts, leading to a pronounced improvement in cardiac structure and
function upon injection into a mouse MI model. More recently, that cocktail of
growth factors was used to create human cardiopoietic MSCs before injecting
them into the endomyocardium of MI patients in a multi-center clinical trial [30].
Indeed, at 6 months post therapy, introduced MSCs improved multiple cardiac
functional parameters such as ejection fraction, fractional shortening, and leftventricular end-systolic volume. Taken together, these studies support two
important notions: 1) Cells can be induced to differentiate into cardiac lineages
and 2) Promoting the cardiopoietic capacity of cells enhances their therapeutic
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potential. Thus, it is likely that overexpressing cardiac TFs in CPCs may prove
advantageous in facilitating their differentiation and enhancing their therapeutic
potential in the clinical setting.

CPCs do not survive well in the host heart
Another major challenge for cardiac cell-based therapy is that the majority
of cells introduced into the heart die within a few days [31, 32]. For instance,
more than 99.5% of MSCs were no longer detected in the left ventricle 4 days
post-transplantation in the heart in a mouse model [33]. Consistent with that, the
vast majority of the 5 x 106 neonatal rat cardiomyocytes injected in cryo- infarcted
rats died within 7 days, as assessed by the TUNEL assay [34]. In order to assess
whether CPCs undergo a similar fate, we previously monitored the retention and
engraftment of CPCs following transplantation into the infarcted heart at serial
time points. Of the 1.0 x 105 intramyocardially injected cells, less than 10% were
still detected 24 hours post-injection [21]. Another study showed that injected
CPCs were no longer detected at 35 days post injection in most of the
investigated rats [17]. This profound loss of cells is thought to be caused by the
poor viability of the transplanted cells in the harsh ischemic environment of the
infarcted heart. Possible causes of premature cell death include: ischemia, host
inflammatory response to infarction, and loss of matrix- and cell-cell interactions
[34].
Thus, several attempts aimed at addressing the poor survivability of CPCs
following transplantation have been carried out. For instance, Fischer et al.
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implemented an ex vivo genetic engineering approach and injected CPCs
overexpressing Pim-1 (a prosurvival serine/threonine kinase) into the infarcted
hearts of mice [35]. Indeed, Pim-1 promoted proliferation of the implanted CPCs
and enhanced their engraftment, leading eventually to a more pronounced
improvement

in

cardiac

function.

Another

approach

utilized

in

vitro

preconditioning of CPCs with cobalt protoporphyrin (a heme oxygenase 1
inducer). Indeed, the preconditioning promoted cell survival following exposure to
H2O2-induced oxidative stress and resulted in the cells releasing higher levels of
prosurvival cytokines, including epidermal growth factor (EGF), fibroblast growth
factors 2 (FGF2), FGF3, BMP3 and erythropoietin [36].
With the ultimate goal of enhancing CPC therapeutic benefit in the
treatment of MI, we sought in this work to address some of the limiting factors
that seem to hinder the progress of CPC-based therapy, such as the poor
survival and differentiation of CPCs. To facilitate CPC differentiation, cardiac
TFs, including Gata4, MEF2C, NKX2.5, TBX5 and BAF60C were overexpressed
(will be discussed in Chapter II). Another genetic-engineering approach aimed at
activating endogenous antioxidants and detoxifying enzymes within CPCs was
utilized to promote cell survival (will be discussed in Chapter III).
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CHAPTER II
TRANSCRIPTION FACTOR-FACILITATED DIFFERENTIATION OF
HUMAN C-KIT+ CPCS

Previous studies have shown that CPCs do not differentiate into functional
cardiac cell types following their introduction to the infarcted heart [11, 17], which
may limit their regenerative potential. On the other hand, cells which express
higher levels of cardiogenic TFs (i.e. more cardiopoietic) have been shown to be
therapeutically superior to less cardiopoietic cells [28, 29]. Thus, with the ultimate
goal of promoting the regenerative potential of CPCs, we endeavored in this work
to induce partial differentiation of CPCs into committed cardiac cell types in vitro.
Once we achieve that goal and obtain more committed CPCs, it would be
interesting down the road to test their therapeutic potential in vivo as compared
to the naïve counterparts.
To promote differentiation of CPCs, the cardiopoietic effect of selected
cardiac TFs was utilized. To that end, genes encoding cardiogenic TFs, namely
GATA binding protein 4 (Gata4), myocyte enhancing factor 2C (MEF2C), a
homeobox TF (NKX2.5), and T-box TF 5 (TBX5), were overexpressed in CPCs
via a lentiviral system. First, we compared the ability of each TF individually to
initiate the differentiation of CPCs into the four main cardiac cell types (i.e.
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cardiomyocytes, smooth muscle cells, endothelial cells, and fibroblasts). In the
next set of experiments, all possible combinations of the aforementioned TFs
were overexpressed in CPCs to determine whether the 4 aforementioned TFs
synergize in promoting CPC differentiation. Also, the effect of differentiation
media/dexamethasone on CPC differentiation was assessed. To assess the
differentiation of CPCs caused by these methods, the changes in expression
levels of markers associated with cardiomyocyte, smooth muscle cell, fibroblasts,
and endothelial cells were analyzed. Quantitative real time PCR (qRT-PCR) was
used to monitor the changes in gene expression at the mRNA level, while
immunocytochemistry and Western blot techniques were utilized to assess them
at the protein level (mCherry-transduced CPCs served as a control). As an
additional assessment of differentiation, microscopy was used to assess
differentiation-associated morphological changes in size, shape, or formation of
characteristic structural changes.
The results showed that Gata4 was most efficient in directing
differentiation of CPCs into cardiomyocytes, smooth muscle cells and fibroblasts
as evidenced by the upregulation of the correspondent cell-specific markers.
However, when Gata4 was combined with differentiation medium and
dexamethasone, CPCs seemed to initiate differentiation into cardiomyocytes
only. These pro-differentiation effects of Gata4 may prove efficient in promoting
complete differentiation of CPCs upon the in vivo transplantation and may thus
have significant implications in maximizing the regenerative potential of CPCs.
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MATERIALS AND METHODS
Isolation and culture of c-kit+/lin- CPCs
After obtaining a written consent, discarded right atrial appendage
specimens from patients at Jewish Hospital in Louisville (KY) were collected
according to a protocol approved by the Institutional Review Board (IRB) on
human subject research at University of Louisville. Patients involved were
undergoing open-heart, on pump, coronary artery bypass surgery and their ages
ranged between 50 and 75 years. Briefly, right atrial appendages were
transported under sterile conditions on wet ice before removal of gross blood and
resection of adipose tissue [10]. The tissue was then washed with PBS, manually
minced then enzymatically digested at 37°C using Worthington Collagenase type
II/Hams F12 solution. The resulting cell suspension was centrifuged before
discarding the supernatant. The cells were then transferred to T75 Flasks
containing Ham’s F12 medium (Gibco), 10% FBS (Gibco), 10 ng/ml recombinant
human basic FGF (PeproTech), 0.2 mM L-glutathione (Sigma), 0.005 U/ml
human erythropoietin (Sigma) and 100 U/ml penicillin/streptomycin (Gibco). The
adherent cells were continuously cultured with medium change every other day
or subcultured every 4-5 days. Cells were passaged 1 time prior to c-kit magnetic
activated cell sorting (MACS) kit using immunomagnetic beads (Miltenyi Biotec)
to enrich for c-kit+/Lin- CPCs. The enriched CPCs were collected for expansion
and/or analysis. Experiments shown in this study are performed on cells isolated
from 1 patient but they have been repeated on isolates from at least one more
patient to corroborate the findings. Figures depict the results from only 1 patient.
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CPC immune magnetic-activated cell sorting (MACS)
70-75% confluent cells at passage 1 were sorted for c-kit using anti-c-kit
(Miltenyi) microbeads and magnetic sorting apparatus. Cells were trypsinized
and then washed twice in ice-cold MACS buffer made according to the
manufacturer’s specifications. All solutions were cooled on ice prior to the sorting
protocol. Cells were immunomagnetically-sorted using MS columns (Miltenyi
Biotec) and pre-separation filters with magnetic stands. To exclude the potential
contamination with lin+ cells (such as T cells, B cells, NK cells, dendritic cells,
monocytes, granulocytes, erythroid cells, and their committed precursors), a
Lineage Cell Depletion Kit (Miltenyi Biotec) was used to purify c-kit+ cell
populations as previously described [37]. The magnetically labeled Lin+ cells
were depleted by retaining them on a MACS column in a magnetic field while
unlabeled lin− cells passed through the column and were collected for further
expansion and/or analysis. c-kit+ enriched cells were plated at subconfluence
then cultured and expanded in vitro. Cells at passages 3-4 were fixed in 3.7%
paraformaldehyde and assessed for c-kit positivity by flow cytometric analysis.

Flow cytometric analysis and immunocytochemistry
Enriched CPCs were trypsinized at passages 3-4, washed with 1x ice-cold
buffer containing 1% bovine serum albumin (BSA)/phosphate buffered saline
(PBS) buffer followed by a second wash in cold PBS. Subsequently, cells were
fixed for 15 minutes at room temperature (RT) using 3.7% paraformaldehyde.
Following washing with PBS, fixed cells were stained for c-kit. Cells were then
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blocked for 10 minutes at RT in 1% BSA buffer prior to staining for c-kit using cterminal specific Santa Cruz C19 rabbit polyclonal IgG anti-human c-kit antibody
for 1 hour in the dark at RT. Isotype rabbit polyclonal IgG was used in parallel as
an isotype control. Cells were then washed with 1% BSA before adding the
secondary antibody, FITC-conjugated donkey anti-rabbit IgG (Invitrogen) for 1
hour in the dark at RT. Flow cytometric analysis was performed using BD
AccuriTM C6 flow cytometer. All analysis gates were set for false positivity of <1%
in respective isotype controls. c-kit positivity was over 70%.

Lentivirus expressing cardiac TFs
Lentivirus expressing the cardiac TFs used in the current study was
produced

using

ViraPowerTM

Lentiviral

Expression

System

(Invitrogen)

according to manufacturer’s instructions. The following MGC verified full-length
cDNA clones for the TFs were purchased from OpenBiosystems: human NKX2.5
cDNA (MHS1010-7430146; Clone ID 5225103; NCBI Accession: BC025711),
human MEF2C cDNA (MHS1010-7295133; Clone ID: 4815933; NCBI Accession:
BC026341), and human TBX5 cDNA (MHS1010-7430001; Clone ID: 5204163;
NCBI Accession: BC027942). A retroviral expression construct for mouse Gata4
(NCBI Accession: NM_008092.3) was a kind gift from Dr. Deepak Srivastava (UC
San Francisco). The coding sequences for each TF or mCherry were PCRamplified using Pfu high fidelity (HF) polymerase (Agilent) and subcloned into
pLenti6/V5-D-TOPO

vector

(Invitrogen)

according

to

the

manufacturer’s

instructions. Primer sequences used for the PCR were the following:
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5`CACCATGTACCAAAGCCTGGCCATG-3`
CGCGGTGATTATGTCCCCATGA-3`

and
for

5`-

Gata4;

5`-

CACCATGTTCCCCAGCCCT-3` and 5`-CCAGGCTCGGATACCATGC-3` for
NKX2.5;

5`CACCATGGGGAGAAAAAAGATTCA-3`

TGTTGCCCATCATTCAGAAAGTC-3`

for

and
MEF2C;

5`5`-

CACCATGGCCGACGCAG-3` and 5`-GCTATTGTCGCTCCACTCTGGC-3` for
TBX5;

and

5`-CACCATGGTGAGCAAGGGC-3`

and

5`-

CTACTTGTACAGCTCGTCCATGCC-3` for mCherry. For generation of pLenti6mCherry expression construct, pmCherry-C2 vector (K. U. Hong) was used as
the PCR template. For generation of 3xFLAG constructs, the following oligos
were synthesized, annealed and inserted into the BamHI site of pLenti6/V5TOPO

vector:

5`GATCCACCATGGATTACAAGGATGACGAC

GATAAGGATTACAAGGATGACGACGATAAGGATTACAAGGATGACGACGAT
AAGGGG3`

and

5`GATCCCCCTTATCGTCGTCATCCTTGTAAT

CCTTATCGTCGTCATCCTTGTAATCCTTATCGTCGTCATCCTTGTAATCCATG
GTG-3`.
Each batch of virus was concentrated 10 times using Lenti-X
Concentrator (Clontech) according to the manufacturer’s instructions and
resuspended in complete CPC medium. Aliquots were made and stored at -80°C
until use. Virus titers were determined by qRT-PCR-based measurement of
integrated copies of viral genome following transduction of CPCs with varying
dilutions of each virus. For calculation of the copy numbers of virus genome
integrated into the host, serial dilutions of pLenti6 vector were used to generate
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the standard curve. Briefly, CPCs transduced with varying dilutions of virus were
harvested after 4 days. Genomic DNA was isolated, and 50 ng of DNA was
analyzed by qRT-PCR as described below. The following primers were used for
the

qRT-PCR

analysis:

5`GCTCAGTTCCAGTTGCTTG-3`

and

5`GCAGTGAGCCAAGATTGCAC-3` for human HLA-A (for human/CPC genomic
DNA)

[21],

and

5`-CATCTTGAGCCCCTGCGGACG-3`

and

5`CCGTCGGCTGTCCATCACTGTC-3` for integrated lentiviral vector. For the
assay, mCherry virus served as a reference. The efficiency of transduction with
each dilution of mCherry virus was assessed by measuring the percentage of
mCherry-positive cells, and it was plotted against the number of viral genomes
integrated into CPCs to obtain a standard curve. Based on the curve, the volume
of virus required to achieve 70-80% transduction efficiency was calculated for
each virus batch.

Lentivirus transduction of CPCs
CPCs were plated on 12-well plates the day before transduction at a
density of approximately 1.0 x 105 cells per well. Next day, the medium was
replaced with 250 µl of complete medium containing appropriate dilution of virus
and 6 µg/ml Polybrene (Sigma), and on the following day, the medium was
replaced with fresh complete media. The cells remained on the same plate until
harvest at specified time points (i.e., 7, 10, or 14 days post-transduction). The
medium was refreshed every 3 days. Each treatment was done in quadruplicate.
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Differentiation medium and dexamethasone treatment
On day 5 after Gata4 transduction of CPCs, regular culturing medium was
replaced with differentiation medium (DMEM (Gibco), 5% FBS and Pen/strep) in
the presence or absence of 10 nM dexamethasone (Sigma). Dexamethasone
was added to the culture every other day for a total of 10 days. On day 14 posttransduction, cells were harvested for qRT-PCR, immunocytochemistry or
Western blot analyses.

RNA isolation and qRT-PCR
Total RNA was isolated from CPCs using RNeasy Mini Kit (with DNase
treatment) (Qiagen) according to the manufacturer’s instructions. cDNA was
synthesized using 250 ng of total RNA using AffinityScript Multiple Temperature
cDNA Synthesis Kit (Agilent) according to the manufacturer’s instructions.
Samples were analyzed for mRNA levels of indicated markers using SYBR
Green Master Mix (Applied Biosystems) and 7900HT Fast qRT-PCR System with
SDS version 2.4.1 (Applied Biosystems). Each gene-specific primer set was
initially validated based on the product size, and each PCR product was then
sequence-verified (data not shown). Sequences of the primers used in the
present study are listed in Table 1.
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Table 1.
List of primers used for qRT-PCR analysis
Target Gene

Gene Symbol

-actinin-2

ACTN2

MHC

MYH6

SMA

ACTA2

ANP

NPPA

BAF60C

SMARCD3

-Actin

ACTB

 -MHC

MYH7

BNP

NPPB

Calponin-1

CNN1

CD31

PECAM

c-kit

KIT

Connexin 40

GJA5

Connexin 43

GJA1

DDR2

DDR2

FLT1

FLT1

FSP-1

S100A4

GAPDH

GAPDH

GATA4

GATA4

GATA4 set 2

GATA4

KDR

KDR

MEF2C

MEF2C

MEF2C set 2

MEF2C

MLC-2V

MLY2

Myocardin

MYOCD

Nkx2.5

NKX2.5

SM-MHC

MYH11

Smoothelin

SMTN

Tbx5

TBX5

forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse
forward
reverse

Primer Sequences (5' to 3')

Product Size (bp)

CATGGGGCAGGCTGGTAGGTG
CCGACCCAGAGTCAGGGATCAAAA
AGGGATAACCAGGGGAAGCACC
AGGTTGAAAAGCACCGCGGG
AGCGACCCTAAAGCTTCCCAGACT
CGGGGGCTGTTAGGACCTTCCC
GGTCGTGCCCCCACAAGTGC
TGGGCTGACTTCCCCGGTCC
TGTCCAGGCCCTGTGGCAGT
TAGCAGGGCTGTGAGGCGCT
GCAGTCGGTTGGAGCGAGCA
ATCACCTCCCCTGTGTGGACTTGG
AGGCCTTGGCCCCTTTCCTCAT
CCTGGTCTGCGCTTCTAGCCG
CCCCGGTTCAGCCTCGGACT
ACGGATGCCCTCGGTGGCTA
AACAGCGCCCAAAGGACGCA
CGCTGCAAACCAAACCGCGT
CAGGCTCCCACTGGCCTGACT
TGCCCTTGCGGTGTTAGGCA
TGGGCCACCGTTTGGAAAGCT
AGGGTGTGGGGATGGATTTGCTCT
AGCAAAAAGCGTGGGCAGTTGGA
TGCCCAGCACGAGCATACGG
CGACCAGTGGTGCGCTGAGC
CCCGCCTGCCCCATTCGATT
CTTTGGCTGGACTCTCCTGGCTC
TCCCATGACGGTTCCGCCAAGA
TGCGAGCTCCGGCTTTCAGG
TTCTCGCTGCCAGGTCCCGA
TGGTTTGATCCTGACTGCTGTCATG
CTCCCGGGTCAGCAGCTCCT
GGTGAAGCAGGCGTCGGAGG
GAGGGCAATGCCAGCCCCAG
CGGCGAGGAGGAAGGAGCCA
TGGGGGCAGAAGACGGAGGG
CCTCTCCTGTGCCAACTGCCAGA
TTCCGCATTGCAAGAGGCCTG
AGCTCAAGGCTCCCTGCCGT
GCGGGGTGAGAGTGGGTTGG
GGACAACAAAGCCCTCAGCAGGT
CCGCCAGCGCTCTTCACCTT
TTGTCCATGTCGGTGCTGGCAT
CGTCCGGCGAAGGTCTGGTG
CTAGGAGGGGGCTCGCTGCT
TGTGCGGCCACGAAGTACCC
GTGCCGGGGGAAACCCTTGT
GAAGCCGAGGGCTTGGTGAGG
CACCGGCCAAGTGTGCGTCT
GCAGCGCGCACAGCTCTTTC
ACGGGAGAGCTGGAAAAGCAGC
TGGCTTGGCGAATTGCCCGT
GATGCTGGTGGACTGTGTGCCC
CAGTTCGTGGCGTCGCAGGT
AGTCCCCCGGAACAACTCGAT
ACAGCAGCTGCACCGTCACC

487
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339
205
100
151
197
142
172
199
184
156
236
226
470
182
145
127
144
132
211
493
354
180
340
117
196
127
235

Tbx5 set 2

TBX5

TEAD1

TEAD1

Thy1/CD90

THY1

Troponin T

TNNT2

VE-Cadherin

CDH5

VEGF

VEGFA

Vimentin

VIM

vWF

VWF

forward
reverse
forward
reverse
forward
reverse
forward
reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

CCTATCAGTGCCGGGTCTGCG
CTCCCAGCTGTGGGGAGCCA
TGGAGCCCCGACATCGAGCA
TGGGAAGGTCGGGCGTGGAA
CCCAGGAGCCGGACACTTCTCA
GGTGGCGTTCCCCAGCCTCA
AGAAGGCCAAGGAGCTGTGGCA
CCAGCGCCCGGTGACTTTAGC
ACAGCATCTTGCGGGGCGAC
CCCGCGGGAGGGCTCATGTA
TGGCAGATGTCCCGGCGAAG
TAGGCTGCACCCCAGGAAGGG
CCGGAGACAGGTGCAGTCCCT
TCATCCTGCAGGCGGCCAAT
ACCCCTGCCCCCTGGGTTAC
TGCAGCCTGGCAGTGATGTCG
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135
351
252
170
178
118
147
322

Immunofluorescence staining
Cells grown on culture plates or glass coverslips were fixed in 3.7%
formaldehyde in PBS for 15 minutes at RT and permeabilized using 0.25% Triton
X-100 in PBS for 10 minutes. Following incubation in the blocking solution (5%
BSA in PBS) for 30 minutes, the cells were incubated in primary antibody
solution (diluted in the blocking solution) for 1 hour at RT and washed twice in
PBS. They were then incubated in a solution of secondary antibodies conjugated
to fluorochromes (diluted in the blocking solution) for 1 hour at RT and washed
twice in PBS. They were finally counterstained with DAPI (4’, 6’-diamidino-2phenylindole) and mounted on glass slides using Fluoromount (Sigma).
Fluorescence images were viewed and acquired using EVOS® FL Cell Imaging
System (Life Technologies).

Western blot
Total protein from transduced CPCs at serial time points was harvested
using sample buffer and boiled for 15 min. Protein concentration was measured
by BCA assay before loading onto a polyacrylamide gel. The proteins
electrophoresed under reducing conditions were then transferred from the gel to
a PVDF membrane. After blocking the membranes for 60 minutes with 5% dry
milk powder and Tris-buffered saline, the membranes were incubated overnight
at 4 °C with primary antibodies against the selected cardiac cell type markers.
Following that, the membranes were washed and then incubated for an hour with
horse radish peroxidase (HRP)-conjugated secondary antibody. Images were
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developed using the ECL plus kit (Bio-rad) and an enhanced chemiluminescent
detection system (Pierce). Densitometry was executed using non-saturated
chemiluminescent membranes exposed and quantified using Fuji LAS-3000 bioimaging analyzer.

Antibodies
The antibodies used for the current study are listed below. KDR/VEFGR2
(mouse monoclonal; ab9530; Abcam); α-SMA (mouse monoclonal; A5228;
Sigma); troponin T (mouse monoclonal; clone 13-11; Thermo Fisher); αsarcomeric actin (mouse monoclonal; A7811; Sigma); FLAG tag (mouse
monoclonal; F-tag-01; Applied Biological Materials); Thy1/CD90 (mouse
monoclonal; clone 5E10; BD Pharmingen); smooth muscle myosin heavy chain
(rabbit polyclonal; Abcam); ANP (mouse monoclonal; clone 23/1; Santa Cruz);
BNP (mouse monoclonal; clone 50E1; Thermo Fisher); c-kit (rabbit monoclonal;
clone YR145; Epitomics); α-tubulin (mouse monoclonal; clone DM1A; Sigma); V5
tag (mouse monoclonal; clone E10; Applied Biological Materials).

Phalloidin Staining
To monitor potential changes in cell morphology induced by TF
overexpression, cultured cells were stained with Phalloidin CruzFluor™ 488
Conjugate (Santa Cruz) according to manufacturer’s instruction. Briefly, cultured
cells were washed twice with prewarmed PBS (pH 7.4) prior to fixation with 3.7%
formaldehyde in PBS for 10-15 minutes. Following 2 rounds of PBS wash, cells

20

were permeabilized using 0.125% Triton X-100 for 5-10 minutes. After another
round of PBS washes, cells were incubated with the green fluorophoreconjugated phalloidin solution for 20 minutes at RT. Fluorescence images were
viewed and acquired using EVOS® FL Cell Imaging System (Life Technologies).

Statistical analyses
All values are expressed as mean ± SE. Analysis of variance (ANOVA)
was performed to compare data among the groups compared to control. Tukey
test was used for other pairwise statistical comparisons. A p value of < 0.05 was
considered statistically significant.
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RESULTS
Introduction of cardiac TFs into CPCs
To promote differentiation of CPCs into functional cardiac cell types,
selected TFs were overexpressed using a lentivirus delivery system. First,
lentiviruses expressing one of the four selected cardiac TFs, Gata4, MEF2C,
NKX2.5, and TBX5 were generated. These TFs either alone or in combination
have been shown to direct differentiation of different cell populations into
cardiomyocytes, including ES cells, extra cardiac mesoderm, and fibroblasts [2326]. For ease of detection, The TFs used in this study were either FLAG-tagged
at the N-terminus (Gata4, MEF2C, and TBX5) or V5-tagged at the C-terminus
(NKX2.5). Following lentivirus production, CPCs were transduced with the
viruses and the protein expression of the 4 TFs was verified by Western blot (Fig.
1). Also, immunocytochemical analysis showed a high efficiency of transduction
ranging between 70 and 90% (Fig. 1). More importantly, the exogenous TFs
were localized to the nucleus as expected (Fig. 1B).

Overexpression of individual TFs in CPCs
TFs were individually introduced into CPCs to assess whether they
promote expression of markers associated with cardiac differentiation [note that
endogenous transcripts of GATA4, MEF2C, and TBX5 but not NKX2.5 were
detectable in naive CPCs (data not shown)]. Transduced cells were cultured for 1
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mCh-

NKX2.5-

NKX2.5

mCh- MEF2C-38

α-tubulin

MEF2C

-54
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-57
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GAPDH
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-52

GAPDH

TBX5-65

α-tubulin

Figure 1. Lentivirus-mediated delivery of transcription factors to CPCs. A,
Images of untranduced and mCherry-transduced CPCs at 4 days posttransduction. Fluorescence of mCherry protein is shown in red. DAPI staining of
nuclei was pseudo-colored in green. B, Immunostaining images for CPCs
transduced with virus expressing 3xFLAG-tagged Gata4, MEF2C, TBX5 or
BAF60C, or V5-tagged NKX2.5 and stained for the indicated epitope (i.e., FLAG
or V5) which is shown in monochrome. DAPI images are shown in lower panels.
C, Western blots confirming successful overexpression of the five TFs in CPCs.
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or 2 weeks with medium change every 3-4 days before using qRT-PCR to detect
the changes in the transcript level of more than 30 different cardiac cell typespecific markers (see Table 2 for the entire set of markers analyzed). In these
experiments, mCherry-transduced CPCs served as a control.
Among the 4 TFs investigated in the study, Gata4 overexpression was
associated with the most pronounced induction of cardiomyocyte, smooth muscle
cell and fibroblast (but not endothelial cell) markers both at 1 and 2 weeks.
Overexpression of Gata4 resulted in upregulating the mRNA transcripts of the
cardiomyocyte markers: brain natriuretic peptide (BNP) and troponin T (TNNT2),
within 1 week of expression (Fig. 2). However, not all cardiomyocyte markers
were upregulated by Gata4 overexpression. Examples include α- and β-MHC
and cardiac actin (ACTC) (data not shown). Interestingly, Gata4 induced the
expression of not only cardiomyocyte markers but also of other cardiac cell types’
markers. For instance, Gata4 overexpression upregulated the transcript levels of
smooth muscle cell markers, including calponin-1 and smooth muscle myosin
heavy chain (SM-MHC) within 2 weeks (Fig. 2). In addition, fibroblast markers
such as THY1/CD90 and fibroblast-specific protein 1 (FSP1; S100A4), were
significantly upregulated following Gata4 expression in CPCs (Fig. 2). However,
no significant induction of endothelial cell markers was detected in Gata4expressing cells (Fig. 2). In fact, Gata4 overexpression resulted in a marginal
decrease in the expression of the endothelial cell marker VE-Cadherin.
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TABLE 2.
Markers of cardiac differentiation examined by qRT-PCR
Cardiomyocyte

Endothelial
Cell

Smooth
Muscle Cell

Transcription
Factors

Mesenchymal/
Fibroblast

Stem
Cell

THY1/CD90

c-kit
(KIT)

ANP (NPPA)

KDR/FLK1

αSMA (ACTA2)

GATA4

BNP (NPPB)

vWF

SM22α (TAGLN)

NKX2.5

α-MHC (MYH6)

CD31 (PECAM1)
VE Cadherin
(CDH5)

SM-MHC (MYH11)

MEF2C

FSP1
(S100A4)
DDR2

Calponin-1 (CNN1)

TBX5

Vimentin (VIM)

Smoothelin
(SMTN)

BAF60C (SMARCD3)

β-MHC (MYH7)
α-Actinin2
(ACTN2)
Cardiac actin
(ACTC)
MLC-2v (MYL2)

VEGF
FLT1

Myocardin (MYOCD)
SRF

Troponin T
(TNNT2)
Connexin 40
(GJA5)
Connexin 43
(GJA1)

TEAD1

TBX20
MYL4
MYL7
SERCA2A
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Figure 2. Effect of individual transcription factors on expression of cardiac
differentiation markers in CPCs. Transcription factors (Gata4 [G], MEF2C [M],
NKX2.5 [N], and TBX5 [T]) were overexpressed in CPCs via a lentivirus-based
delivery system. Following transduction, cells were cultured for 1 or 2 weeks. At
each time point, cells were harvested, and relative changes in mRNA levels of
indicated genes were measured using qRT-PCR. The level of indicated transcript
in each group was compared to that of mCherry-expressing control group (set at
1), and is expressed as a relative fold change. For each condition, n = 4. Bar
graphs show mean ± SEM. *, p < 0.05 (vs mCherry-CPCs). †, not detected.
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To assess any morphological changes in CPCs that may accompany
Gata4-directed differentiation, phalloidin staining (which stains F-actin and shows
the overall cytoskeleton), was utilized. Indeed, Gata4-overexpressing cells
exhibited observable changes in cell morphology. The cells grew in size,
resumed a polygonal morphology, and often exhibited prominent stress fibers,
while mCherry-expressing cells retained their spindle-shaped morphology (Fig.
3A).
In addition to Gata4, TBX5 overexpression also exhibited a cardiogenic potential,
albeit to a lesser extent. Genetic introduction of TBX5 induced few cardiomyocyte
markers such as atrial natriuretic peptide (ANP) and TNNT2 (Fig. 2). However,
TBX5 did not upregulate other cardiomyocyte markers such as α-, β-MHC and
BNP by 2 weeks (data not shown and Fig. 2). Also, TBX5 transiently upregulated
the endothelial cell marker KDR (vascular endothelial growth factor receptor 2;
VEGFR2) but not VE-Cadherin, CD31 or vWF (Fig. 2 and data not shown). On
the other hand, TBX5 expression resulted in downregulation of smooth muscle
cell markers such as SM22α and αSMA (Fig. 2). Also similar but less pronounced
than what was observed with Gata4 overexpression, TBX5 induced prominent
morphological changes in some CPCs with the distinctive appearance of stressfiber like structures and the enlarged cell phenotype (data not shown). Taken
together, these findings show that Gata4 overexpression was associated with the
most differentiation-promoting effect in CPCs, as reflected by induction of
markers of at least three cardiac cell types (i.e. cardiomyocytes, smooth muscle
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Figure 3. Gata4-induced changes in gene expression and morphology. A,
phase-contrast images of mCherry- and Gata4-overexpressing CPCs (upper
panels). mCherry- and Gata4 virus-transduced CPCs were stained with Alexa Fluor
488-conjugated phalloidin to stain the cytoskeleton at 2 weeks post-transduction
(lower panels). Gata4 overexpression changed the normal elongated shape of CPCs
into a wide polygonal morphology. B, mCherry- and Gata4-transduced CPCs stained
for the indicated markers at 2 weeks post transduction. Gata4-expressing cells
exhibiting supranuclear staining of BNP are indicated by the arrows.
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cells and fibroblasts). On the other hand, TBX5 overexpression resulted in less
pronounced induction of cardiomyocyte and endothelial cell markers.
With regard to MEF2C or NKX2.5, their overexpression unexpectedly did
not significantly increase the expression of genes associated with cardiac
differentiation. NKX2.5 expression was associated with a trend of increasing the
expression of the atrial cardiomyocyte marker connexin 40 and the endothelial
cell marker KDR after 2 weeks (Figs. 2 and 4) but that induction did not reach
statistical significance. MEF2C overexpression on the other hand was often
associated with a decrease in the transcripts of smooth muscle cell markers
(e.g., Calponin-1 and SM22α), compared to the control (Figs. 2 and 4). Also,
MEF2C seemed to suppress some cardiomyocyte markers (e.g., TNNT2 and
connexins 40) and fibroblast markers (e.g., Thy1/CD90) although that did not
reach statistical significance (Fig. 2 and 4).
To confirm the above observed changes in cardiac cell markers, protein
expression of selected markers was assessed using immunofluorescence
staining and Western blot analysis. For each assay, cells at 2 weeks posttransduction were analyzed. In line with the aforementioned qRT-PCR data,
Gata4-overexpression in CPCs resulted in BNP upregulation and that was
observed mainly in the supranuclear region (Fig. 3B), in consistence with a
previous report (26). Also, Gata4 overexpression was associated with a
significant induction of the fibroblast marker Thy1/CD90 in CPCs, corroborating
the qRT-PCR data (Fig. 3B). Interestingly, although αSMA mRNA level was not
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Figure 4. Co-expression of transcription factors in combination in CPCs.
Cells were transduced with combinations of Gata4 [G], MEF2C [M], NKX2.5 [N],
and TBX5 [T] and then cultured for 10 days prior to mRNA profiling using qRTPCR. mCherry-transduced cells served as a negative control and was set at 1.
The level of indicated transcript in each group was compared to that of mCherry
control group, and is expressed as a relative fold change. For each condition, n =
4. Bar graphs show mean ± SEM. *, p < 0.05 (vs mCherry-CPCs).
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upregulated by Gata4 (Fig. 2), its protein level was significantly upregulated as
assessed by immunocytochemistry (Fig. 3B) and was confirmed by Western blot
(data not shown), suggesting a Gata4-induced post-translational stabilization of
αSMA. These observations are consistent with the previous qRT-PCR data
mentioned earlier and further support the role of Gata4 in promoting
differentiation of CPCs into cardiomyocytes, smooth muscle cells and fibroblasts.
It should be noted that not all markers upregulated at the transcriptional level
were associated by detectable protein expression (data not shown), suggesting
that the level of induction of some markers by the TFs is minimal.

Effects of overexpression of TFs in combination
Based on the aforementioned data, we hypothesized that a combination of
TFs may be needed for the TFs to achieve synergism and to further promote
differentiation of CPCs. To test that, the four aforementioned TFs (i.e. Gata4 [G],
MEF2C [M], NKX2.5 [N], TBX5 [T]) were introduced into CPCs in every possible
combination via lentivirus. In total, 15 combinations of the aforementioned TFs
were used (see Fig. 4). CPCs transduced with each combination of viruses were
cultured for 10 days, and then analyzed for changes in mRNA expression of
differentiation markers by qRT-PCR. The data show that overexpression of the
correct set of TFs in each group was confirmed by quantitative as well as semiquantitative RT-PCR (Fig. 5C and data not shown).
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Figure 5. Effect of transcription factor overexpression on the level of
endogenous transcription factors. A and B, Cells were transduced with
combinations of Gata4 [G], MEF2C [M], NKX2.5 [N], and TBX5 [T] and then
cultured for 10 days prior to mRNA profiling using qRT-PCR. mCherrytransduced cells served as a negative control (not shown) and was set at 1. The
level of indicated transcript in each group was compared to that of mCherry
control group (set at 1), and is expressed as a relative fold change. For each
condition, n = 4. Bar graphs show mean ± SEM. *, p < 0.05 (vs mCherry-CPCs).
C, Selected PCR products resulting from experiments described in Figures 4 and
5 were electrophoresed on agarose gel and stained by ethidium bromide.
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Surprisingly, additive or synergistic effects of TFs were rarely observed.
Only ANP, connexin 40 and α-actinin-2 were most upregulated in cells
expressing all four TFs (Fig. 4). By and large, TFs overexpressed in combination
were less effective in inducing cardiac differentiation markers when compared to
single TFs. For example, induction of BNP, TNNT2, and THY1/CD90 mRNAs by
Gata4 and induction of KDR by TBX5 were attenuated when other TFs were
coexpressed (Fig. 4).
Next, the ability of overexpressed TFs to promote transcription of their
endogenous counterparts was also assessed. Most of the TFs, whether alone or
in combination, did not significantly induce their endogenous counterparts (Fig.
4). For instance, none of the 15 combinations tested was able to upregulate the
transcript of endogenous Gata4 (Fig. 4). The only exception was the upregulation
of the endogenous MEF2C transcript by MEF2C overexpression (Fig. 5A).
Similarly, the combinations did not promote the transcription of other important
cardiac TFs including serum response factor (SRF) and myocardin (MYOCD); a
master regulator of smooth muscle gene expression (Fig. 5A). In fact, MYOCD
mRNA level was suppressed by the overexpression of MEF2C and TBX5 (Fig.
5A). In fact, only Gata4 overexpression (individually) was able to reproducibly
drive an upregulation in BAF60C, a chromatin remodeling TF, and in TEAD1 (a
cardiac transcriptional enhancer) (Fig. 4 and data not shown). Taken together,
these data show that only Gata4 overexpression (alone) activated some
endogenous cardiac TFs.
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Overexpressing BAF60C in CPCs
With the limited induction of the cardiac gene markers observed with
overexpressing the selected 4 TFs and for the purpose of further attaining more
pronounced differentiation of CPCs, BAF60C was added to the list of tested TFs.
BAF60C possesses a helicase and an ATPase activity and is part of a chromatin
remodeling SWI/SNF-like multi-subunit BAF chromatin remodeling complex.
These activities enable Baf60c to play an important role in reorganizing the
chromatin structure and facilitating the binding of TFs to their target genes [38].
Indeed, Baf60c has been shown to promote interactions between TFs (e.g.,
Tbx5, Nkx2.5, and Gata4) and the BAF complex, to enhance transactivation of
cardiac genes during mammalian heart development [39]. In addition, Baf60c
assisted Gata4 and Tbx5 to reprogram extra-cardiac mesoderm into heart tissue
in mice [23].
The qRT-PCR analysis showed the presence of BAF60C transcript in
undifferentiated CPCs (Fig. 6B). However, it was unknown if the protein was
present at a sufficient level or if functional BAF complexes were present. Next,
the role of BAF60C in promoting differentiation and its ability to potentiate the
effects of Gata4 or TBX5 was investigated [The latter two TFs showed the most
pronounced induction of differentiation markers and were thus included (Figs. 2
and 4). To that end, CPCs were forced to overexpress BAF60C [B], Gata4 [G],
and TBX5 [T] individually and in every possible combination. Following two
weeks of culture, cells were analyzed for changes in cardiac gene expression by
qRT-PCR.
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Figure 6. Effect of overexpression of BAF60C, Gata4 and TBX5 on
regulation of cardiac differentiation markers in CPCs. A, CPCs transduced
with different combinations of BAF60C [B], Gata4 [G], and TBX5 [T] via lentivirus
and cultured for 2 weeks prior to mRNA profiling using qRT-PCR. mCherrytransduced cells served as negative control. The level of indicated transcript in
each group was compared to that of mCherry-expressing control group (set at 1),
and is expressed as a relative fold change. For each condition, n = 4. Bar graphs
show mean ± SEM. *, p < 0.05 (vs mCherry-CPCs). B, Semi-quantitative qRTPCR analysis showing increased expression of the indicated TFs in each
treatment group. β-actin served as a loading control.
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Unexpectedly, BAF60C expression did not upregulate any of the tested
differentiation markers (Fig. 6). In fact, BAF60C had either no effect or
downregulated the transcript levels of most investigated markers including the
cardiomyocyte markers BNP and TNNT2, the smooth muscle marker α-SMA, the
endothelial cell marker KDR, and the fibroblast markers Thy1/CD90 and FSP-1
(Fig. 6). In addition, BAF60C antagonized several Gata4 and/or TBX5 effects and
in CPCs. For instance, BAF60C blunted Gata4-induced upregulation of BNP,
TNNT2, THY1/CD90, and FSP-1 transcripts (Fig. 6). These observations suggest
that BAF60C suppresses cardiac gene expression in CPCs and that
downregulation of its expression may be needed for CPCs to differentiate into
functional cardiac cell types.

Role of differentiation medium and/or dexamethasone
The use of a serum-reduced medium has been shown to drive the
differentiation of multiple stem cells into cardiomyocytes [33, 40]. Similarly,
adding dexamethasone to the culturing medium has been shown to direct cells
into the cardiomyocyte lineage [41, 42]. With the limited CPC differentiation
caused by TF-delivery in this study, we examined whether combining Gata4
overexpression and differentiation media/ dexamethasone have a synergistic
effect in promoting differentiation of CPCs.
Interestingly, in comparison to the effect of differentiation media, Gata4
overexpression

alone resulted in

a more

pronounced upregulation of

cardiomyocyte markers. For instance, Gata4 overexpression caused a ~13 fold
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induction in BNP whereas culturing in differentiation medium caused only a ~7
fold induction (Fig. 7). In line with that, Gata4 overexpression had a consistent
trend (yet not significant) of upregulating TNNT2, whereas the differentiation
medium had no effect (Fig. 7). More importantly, a synergistic effect was
observed when the differentiation medium was accompanied with Gata4
overexpression. For instance, the ~7 fold induction in BNP caused by the
differentiation medium tripled when Gata4 was overexpressed (Fig. 7). Also, the
combination of Gata4/differentiation was significantly synergistic in upregulating
TNNT2 mRNA level, increasing its level by 53 folds (Fig. 7). More interestingly,
Gata4 overexpression in CPCs that were cultured in differentiation medium
containing dexamethasone had an even more pronounced synergistic effect in
upregulating TNNT2 expression, reaching 170 fold greater induction as
compared to mCherry-expressing cells (Fig. 7). These findings suggest that
Gata4 combined with the dexamethasone/differentiation medium regimen has a
strong synergistic effect in upregulating cardiomyocyte markers.
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Figure 7. Effect of overexpression of Gata4, differentiation medium and/or
10 nM dexamethasone on regulation of cardiomyocyte markers in CPCs.
CPCs transduced with Gata4 [G] via lentivirus and cultured for 2 weeks prior to
mRNA profiling using qRT-PCR. Differentiation medium composed of DMEM
medium containing 5% FBS was added on day 5 post Gata4 transduction and
then changed freshly every other day. 10 nM dexamethasone was also added
every other day starting on day 5 post-transduction. mCherry-transduced cells
served as negative control and were set at 1. The level of indicated transcript in
each group was compared to that of mCherry-expressing control group, and is
expressed as a relative fold change. For each condition, n = 4. Bar graphs show
mean ± SEM. *, p < 0.05 (vs mCherry-CPCs unless other way illustrated).
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Discussion
Although CPCs have the potential to generate at least three of the cell
types that reside in the heart muscle (cardiomyocytes, smooth muscle cells and
endothelial cells) [9], they do not exhibit that ability upon reintroduction into the
infarcted heart [11, 17]. Reasons for that could be related to the cell isolation
process, culturing conditions or the introduction to harsh conditions within the
infarcted myocardium. This limited differentiation of CPCs is thought to affect
their regenerative potential in MI cell-based therapy, particularly because studies
have shown therapeutic superiority of cells that are more committed to the
cardiac cell lineages. For instance, MSCs expressing the cardiogenic TFs Gata4
and Csx/Nkx2.5 (Csx is the orthologue of Nkx2.5 in mice) proved superior to their
naïve counterparts in alleviating ischemic cardiomyopathy [28]. Indeed, the
genetically-engineered

MSCs

improved

ejection

fraction

and

fractional

shortening, and resulted in lower deposition of collagen within the myocardium.
Upon analysis of the implanted cells, most MSCs overexpressing Csx/Nkx2.5
and GATA-4 also coexpressed the cardiomyocyte markers TNNT2 and connexin
43, indicating partial differentiation into cardiomyocytes, and were associated
with higher density of micro-vessels. In another study, bone marrow MSCs,
isolated from 12 patients undergoing coronary artery bypass surgery, were
injected into the infarcted hearts of 8- to 12-week-old immunocompromised mice
[29]. Upon functional analysis, cells from only 2 patients led to functional cardiac
benefit in the infarcted mice. These reparative MSCs were distinguished from the
non-effective counterparts by the robust expression of the cardiac TFs NKX-2.5,
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TBX5, MEF2C and MESP1. Interestingly, upon induction of the cardiac program
in the non-reparative MSCs by a cocktail of growth factors (including TGFβ1,
BMP-4, activin-A, retinoic acid, FGF-2, IGF-1, and IL-6), the cells upregulated
NKX2.5, TBX5 and MEF2C expression and resulted in improved myocardial
functional recovery when injected in vivo. These studies support that
upregulating expression of cardiac TFs in CPCs (i.e. prompting them to acquire a
more committed phenotype) is needed to promote their therapeutic benefit for
heart cell-based therapy.
Protocols to facilitate differentiation of c-kit+ CPCs include the use of
differentiation media, dexamethasone, 5-azacytidine followed by TGF-β1, or coculturing with neonatal rat cardiomyocytes [9, 10, 43-45]. However, these
protocols have not been reproducibly effective in facilitating differentiation of
CPCs. We, thus, sought to enhance the differentiation of CPCs into cardiac cell
types via the introduction of selected cardiac TFs (GATA4, MEF2C, NKX2.5, and
TBX5), which have shown to be able to drive cardiogenesis [23-26]. To that end,
the 4 TFs were overexpressed individually and in various combinations in CPCs.
Only Gata4 individually was able to reproducible induce significant effects. By
mRNA analysis, Gata4 was shown to upregulate markers of cardiomyocytes
including BNP, connexin 40, BAF60C, and TNNT2. Gata4 also upregulated the
smooth muscle cell markers: SM-MHC and calponin 1, as well as the fibroblast
markers: THY1/CD90 and FSP-1 (Fig. 2 and 4). However, there was no
accompanying induction of endothelial cell markers, suggesting that Gata4
directs the differentiation of CPCs into cardiomyocytes, smooth muscle cells and
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fibroblasts but not endothelial cells. It was also interesting to find that Gata4induced upregulation of cardiomyocyte markers (such as BNP and TNNT2) were
more pronounced than that of the differentiation medium (5% FBS-containing
DMEM) (Fig. 7). That suggests that overexpressing Gata4 is more effective than
the differentiation medium in directing differentiation of CPCs into the
cardiomyocyte lineage. In line with these pro-differentiation roles of Gata4 in
CPCs, isolated CPCs from adult rat hearts up-regulated GATA-4 expression over
long-term culture and were then characterized by enhanced differentiation into
cardiomyocytes [46].
Interestingly, a synergy between Gata4 and the differentiation medium
was evident in facilitating differentiation of CPCs into cardiomyocytes, as
evidenced by the induction of the cardiomyocyte markers BNP and TNNT2 (Fig.
7). There was an even more pronounced synergism in inducing cardiomyocyte
markers (e.g. TNNT2), by adding dexamethasone to the differentiation medium
and Gata4 overexpression, (Fig. 7). However, no induction of smooth muscle
cell, endothelial cell, or fibroblast markers was noted with the aforementioned
regimens (data not shown). These findings suggest that although Gata4 directs
CPC differentiation into 3 cardiac cell lineages (cardiomyocytes, smooth muscle
cells and fibroblasts), it directs the differentiation into only cardiomyocytes if
combined with dexamethasone-containing differentiation media.
In addition to its role in driving differentiation, Gata4 has been reported to
play other beneficial roles in the heart. For instance, Gata4 has been shown to
possess a prosurvival effect, serving as an upstream activator of the
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antiapoptotic gene Bcl-X in differentiated postnatal cardiomyocytes [47]. Indeed,
mouse heterozygotes for a null Gata4 allele had higher susceptibility to
doxorubicin-induced

cardiotoxicity

which

was

rescued

by

genetic

or

pharmacological enhancement of Gata4 [47]. Also, Gata4 has also been shown
to promote cardiac angiogenesis. For instance, conditional overexpression of
GATA4 in adult cardiomyocytes increased myocardial capillary formation and
increased coronary flow reserve and perfusion-dependent cardiac contractility
[48]. These studies suggest that Gata4 activation in CPCs used for heart repair
may have multi-faceted benefits, including promoting CPC differentiation and
survival, as well as promoting cardiac angiogenesis.
Although NKX2.5 plays a pivotal role in early heart development and
cardiac function [49-51], its overexpression in CPCs did not robustly upregulate
differentiation markers. NKX2.5 led only to a slight increase in the mRNA level of
connexin 40 and KDR (Fig. 2 and 4). Also, NKX2.5 also did not synergize or
potentiate the effects of the other TFs analyzed in the study. Although this was
unexpected, a previous report has shown a similar antagonistic role of NKX2.5 in
promoting differentiation into cardiomyocytes [26]. These data suggest specific
requirements for the cardiogenic effect of NKX2.5 that were missing in the in vitro
conditions of the current study or that NKX2.5 has a cell- or time- or
developmental stage-specific effect.
Previous reports suggested that cardiac TFs interact with one another to
co-regulate cardiogenesis. For instance, co-expression of GATA-4 and Nkx2.5
resulted in a synergistic activation of the ANP promoter in heterologous cells.
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The synergy was associated with a physical interaction between the 2 TFs
observed in vitro and in vivo [52]. Furthermore, Nkx2.5 has been shown to
associate with Tbx5 to promote cardiomyocyte differentiation [53]. On the other
hand, there are also indications in the literature suggesting antagonism between
some cardiac TFs. For instance, the synergistic activation of the connexin 40
promoter induced by NKX2.5 and GATA4 was suppressed by co-expression of
TBX5 [54]. In line with that, our results show that overexpressing TFs in
combination did not synergize in directing CPC differentiation. Indeed, except for
the markers ANP, connexin 40 and α-actinin2, expressing all the 4 TFs (Gata4,
NKX2.5, MEF2C and TBX5) in CPCs led often to suppressing the transcription of
differentiation markers compared to single TFs (Fig. 4). These mixed results
observed when multiple TFs are expressed in CPCs, as shown in our study and
in some previous reports, suggest a gene-specific synergism/antagonism of TFs,
reflecting the complexity of the regulatory transcription network within CPCs.
BAF60C was added to the pool of investigated TFs in this study because it
is a subunit of the BAF complexes that is involved in promoting interactions
between cardiac TFs and the BAF complex, thereby promoting cardiogenesis
[39]. To that end, BAF60C, Gata4 and/or TBX5 were overexpressed in every
possible combination in CPCs. However, the qRT-PCR data (see Fig. 6) show
that BAF60C suppressed the expression of most cell differentiation markers,
suggesting that it inhibits CPC differentiation.
Although speculative, the inability of BAF60C, MEF2C, NKX2.5 and TBX5
(with the exception of Gata4) to promote robust CPC differentiation may be due
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to one of the following: 1) it is possible that a precise temporal coordination is
needed for these TFs to transactivate one another and drive cardiogenesis. In
this study however, TFs were expressed at the same time and for the same
period. 2) Duration of TF overexpression may need to be longer than the 2
weeks applied in this study 3) The chromatin epigenetic status (i.e. methylation
and acetylation) of the promotor regions of the target genes of our investigated
TFs may have not been optimal and may have inhibited differentiation [55]. 4)
Protocols of isolation and culturing and other in vitro conditions of CPCs have
affected their ability to differentiate. 5) CPCs used in the study are not clonallyexpanded cells and thus may constitute a heterogeneous population of primitive
and more committed

progenitors

[56, 57],

with

varying potentials of

differentiation. 6) The cells used in this study are derived from relatively aged
patients and thus may have lost their full differentiation potential. 7) Complete
differentiation of CPCs may, in fact, never be achieved ex vivo due to a loss of
one or more of cardiac tissue micro-environmental cues or because the
surrounding milieu in vitro used in our experiments does not recapitulate the
physiological cardiac tissue.
Nonetheless, despite the insufficiency of Gata4 to induce complete
differentiation of CPCs, partial differentiation of CPCs may be all that is required
to achieve a superior therapeutic effect for MI. It is possible that some Gata4expressing CPCs may reach complete differentiation upon injection in the
differentiation-conducive physiological environment of the mammalian heart. In
support of that, Qian et al. have shown that TF-mediated reprogramming of
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cardiac fibroblasts into cardiomyocytes is easier in the native cardiac tissue as
compared to cells grown in culture [58].
In conclusion, overexpressing Gata4 alone or in the presence of
differentiation medium and dexamethasone robustly upregulated markers of
cardiomyocytes, smooth muscle cells, and fibroblasts, suggesting a pivotal role
of Gata4 in facilitating CPC differentiation. Unexpectedly, however, BAF60C,
MEF2C, NKX2.5, and TBX5 did not significantly synergize or facilitate Gata4
effects, underscoring the complexity of the interactions and effects of cardiac
TFs.
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CHAPTER III
PROMOTING SURVIVAL OF HUMAN C-KIT+ CPCS

Poor survival of cells engrafted in the heart is one of the major hurdles that
slow the progress of heart cell-based therapies [21, 22]. That rapid cell loss does
not allow implanted cells to remain long in the diseased cardiac tissue, and may
thus limit their therapeutic benefit. Unfortunately, the exact cause of cell death is
not well-defined although it is likely to be due to the ischemia within the infarcted
heart, the host inflammatory response, and/or anoikis [34].
Ischemia in the infarcted heart has a deleterious effect not only on
endogenous cardiac cells but also on cells introduced to the heart for therapeutic
purposes. In addition to the ischemia-mediated oxygen and nutrient deprivation
[34], ischemia generates detrimental high levels of reactive oxygen species
(ROS) [59-61]. Indeed, Kolamunne et al. have shown that hypoxia produces high
amounts of mitochondrial superoxide, which mediate the toxicity observed in
cardiac progenitors [62]. Produced ROS could be damaging to stem cells in
multiple ways. For instance, high levels of ROS injure cell membranes and
increase the permeability of the mitochondrial membrane, leading to impairment
of intracellular Ca2+ homeostasis [63]. ROS also transduce the deleterious effects
caused by inflammatory cytokines [tumor necrosis factor-α (TNF-α), IL-1β and IL-
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6] through a TNF-α receptor/caspase pathway [63]. ROS can even impair other
crucial stem cell properties such as migration and differentiation [64].
One interesting molecule that may be utilized to promote cell viability in
the presence of high oxidative stress is Nrf2. Nrf2 is a TF that efficiently combats
oxidative stress and may thus be utilized to enhance stem cell survival [65].
When activated, Nrf2 upregulates the transcription of various genes involved in
cellular protection against oxidative stress, including heme oxygenase 1 (HO-1),
NAD(P)H

quinone

oxidoreductase

1

(Nqo1),

sulfiredoxin

1

(SRXN1),

peroxiredoxin, epoxide hydrolase, peroxidases, and glutathione- (GSH)synthesizing enzymes [66, 67]. Nrf2 also exerts additional beneficial effects by
upregulating production of prosurvival cytokines and by moderating inflammation
and immune response [68-70]. The significance of Nrf2 and its prosurvival role
have been shown in multiple systems. For instance, preconditioning astrocytes
by adding sulforaphane (a Nrf2 stabilizing isothiocyanate abundant in broccoli)
upregulated the expression of the reactive quinone quencher Nqo1 and
conferred protection against oxidative stress [71]. Another study showed that
neurons that lack Nrf2 activity in knock-out mice were more susceptible to
oxidative stress as compared to the wild type counterparts (Nrf2+/+) [72]. When
Nrf2 activity was restored in the Nrf2-/- neurons by overexpressing the encoding
gene, the neurons regained the ability to resist oxidative stress. Consistent with
that, activating Nrf2 chemically or via adenovirus-mediated Nrf2 delivery
protected neural stem cells from oxidative stress [64]. In the context of human
hematopoietic stem progenitor cells, Nrf2 was shown to abrogate oxidative
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stress-induced toxicity and to upregulate production of prosurvival cytokines such
as BCL2A1 and IL-10 [68]. These studies prompted us to hypothesize that Nrf2
activation in CPCs is a good strategy to help promote survival of CPCs under
high oxidative stress conditions in vitro. The ultimate long-term goal is to obtain
genetically-modified cells that can resist the oxidative stress within the infarcted
heart in vivo.
To enhance the activity of Nrf2 in CPCs, it is vital to understand how Nrf2
is regulated under both physiological and stressed conditions. Under normal
conditions, Nrf2 is sequestered in the cytoplasm by binding to the actin-tethered
Kelch like-ECH-associated protein 1 (Keap1) [73]. Keap1 recruits Cullin 3 (Cul3),
a subunit of the E3 ligase complex, by interacting with its N-terminal region.
Recruited Cul3, in turn, marks Nrf2 for proteosomal degradation and thus
prevents Nrf2 translocation and subsequent activation into the nucleus [74]. In
contrast, under stressful conditions, ROS and electrophiles disrupt critical
cysteine residues (including Cys 151) within Keap1, which abolishes the
interaction between Keap1 and Nrf2. This allows Nrf2 to freely translocate into
the nucleus and bind to antioxidant response element (ARE) sites at the
upstream promoters of Nrf2 target genes [75]. To bind to ARE, Nrf2 needs first to
heterodimerize with its binding partner (small maf protein). DNA binding initiates
transcription of several antioxidant genes [76]. In attempt to promote Nrf2 activity
in CPCs, our lab generated a constitutively active form of Nrf2 (caNrf2) by
deleting 88 amino acids at the N-terminus. The mutation stabilizes Nrf2 by
abolishing the interaction of Nrf2 with Keap1, and thus activates Nrf2-mediated
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antioxidant pathways [73]. Next, caNrf2 was expressed in CPCs and its ability to
promote survival was assessed in vitro.
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MATERIALS AND METHODS
Isolation and culture of c-kit+/lin- CPCs
See “methods and materials” section in Chapter II.

Immunofluorescence staining and Western blot analysis
See “methods and materials” section in Chapter II. Nrf2 antibody (rabbit
polyclonal; GTX61763) was purchased from GeneTex.

Production of caNrf2 lentivirus and lentivirus-mediated transduction
Lentivirus expressing caNrf2 used in the current study was produced
using ViraPowerTM Lentiviral Expression System (Invitrogen) according to
manufacturer’s instructions. The pcDNA3-Myc3-Nrf2 (Addgene plasmid 21555)
which contains the full-length human Nrf2 coding sequences was purchased from
Addgene (www.addgene.org). caNrf2 was generated in our lab by deleting 88
amino acids at the N-terminus of Nrf2. That mutation is at the locus of Nrf2
responsible for Keap1 binding, leading to constitutive activation of caNrf2. The
coding sequences for caNrf2 or mCherry were PCR-amplified using Pfu HF
polymerase (Agilent) and subcloned into pLenti6/V5-D-TOPO vector (Invitrogen)
according to the manufacturer’s instructions. Primers used for the PCR were the
following:

5’-GTTTTTCTTAACATCTGGCTTCTTACTTTTG-3’

and

5’-

CACCATGCAGCACATCCAGTCAGAAACCA-3’. For generation of pLenti6mCherry expression construct, pmCherry-C2 vector (K. U. Hong) was used as
the PCR template. For generation of 3xFLAG-caNrf2, the following oligos were
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synthesized, annealed and inserted into the BamHI site of pLenti6/V5-TOPO
5’-

vector:

GATCGACCATGGATTACAAGGATGACGACGATAAGGATTACAAGGATGACG
ACGATAAGGATTACAAGGATGACGACGATAAGG-3’

and

5’-

GATCCCTTATCGTCGTCATCCTTGTAATCCTTATCGTCGTCATCCTTGTAATC
CTTATCGTCGTCATCCTTGTAATCCATGGTC-3’.

Each batch of virus was

concentrated 10 times using Lenti-X Concentrator (Clontech) according to the
manufacturer’s instructions and resuspended in complete CPC media. Aliquots
were made and stored at -80°C until use.

Inducing oxidative stress in CPCs
CPCs cultured in 6-well plates and supplemented with regular complete
medium were transduced with mCherry- (control) or caNrf2-expressing
lentiviruses. Transduced cells were cultured with medium change every 3 days
for a total of 6 days to allow expression and activation of the inserted gene. The
cells were then washed with PBS, trypsinized and counted using a
hemocytometer. Subsequently, 1.0 x 104 CPCs were plated per well of a 96 well
plate. The cells were then exposed to oxidative stress-inducers such as 2, 3dimethoxy-1, 4-naphthoquinone (DMNQ) or hydrogen peroxide (H2O2). DMNQ
was used at either a concentration of 25 μM in regular complete medium or at a
concentration of 12 μM in serum-free medium for a period of 4-5 days. H2O2 was
applied at a 1.5 mM concentration for a total of 6 hours. Both DMNQ and H2O2
were freshly prepared from stock solutions prior to each experiment. Following
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oxidative-stress exposure, viability assays were performed to determine the
number of surviving cells at serial time points.

Prestoblue assay
PrestoBlue (Invitrogen) cell assay was used to assess cell viability on 1.0
x 104 CPCs that were plated on a 96-well plate. PrestoBlue solution contains
resazurin, which is a blue non-fluorescent substance that enters viable cells and
then gets converted by the reducing intracellular environment into a red &
fluorescent metabolite. Cell viability can thus be estimated by measuring
absorbance or fluorescence. The PrestoBlue assay was performed according to
manufacturer’s instructions. Briefly, the 10x reagent was diluted in the culturing
medium to make a 1x reagent solution. At the time of analysis, culturing medium
was replaced with the freshly prepared 1x Prestoblue solution and incubated at
37° C for an hour. The viability was then assessed by reading the fluorescence at
Ex/Em 560/590 nm. All experiments were done in quadruplicates.
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RESULTS
Overexpressing caNrf2 in CPCs
Previous studies have shown that Nrf2 activation has conferred protection
to multiple cell types exposed to high levels of oxidative stress [64, 68]. Thus, we
hypothesized that Nrf2 activation by forced expression of the encoded gene will
promote CPC survivability. To that end, FLAG-tagged caNrf2 was overexpressed
in CPCs using a lentivirus delivery system. Western blot verified successful
caNrf2 expression in CPCs and immunocytochemistry showed 70-90%
transduction efficiency for both mCherry- and caNrf2-viruses (Fig. 8).

caNrf2 induces multiple antioxidant genes in CPCs
Following the successful expression of the caNrf2 construct, the effect of
caNrf2 gene transfer on the expression of antioxidant genes was investigated.
CPCs were transduced with mCherry- (control) or caNrf2-expressing lentiviruses.
Six days post transduction, the gene expression of selected Nrf2 target genes
were examined at the mRNA and protein levels using qRT-PCR and Western
blot. Indeed, transduction of CPCs with caNrf2-lentivirus significantly increased
the expression of Nrf2 target genes, most notably HO-1 (Fig. 9). HO-1 is a
stress-inducible gene whose expression is upregulated in response not only to
ROS but also to a large number of other internal and external factors that cause
cellular stress [77]. In addition to HO-1 induction, caNrf2 caused a significant
upregulation of other Nrf2 target gene transcripts including NAD(P)H quinone
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Figure 8. Lentivirus-mediated delivery of caNrf2 into CPCs. A, Western blot
images confirming caNrf2 protein expression in CPCs compared to mCherrytransduced cells at day 5 post-transduction. GAPDH was used as a loading
control. B, Immunostaining images showing level of forced expression in CPCs
transduced with mCherry- (left panel) or 3xFLAG-tagged caNrf2-virus (right
panel). DAPI images are shown in lower panels.
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Figure 9. caNrf2 overexpression in CPCs upregulates Nrf2 target genes. A,
mCherry and caNrf2 were overexpressed in CPCs via a lentivirus-based delivery
system. At day 6 post-transduction, cells were harvested, and relative changes in
mRNA transcripts of the indicated Nrf2 target genes were measured using qRTPCR. The level of each transcript was compared to that of mCherry-expressing
control group, and is expressed as a relative fold change. B, Western blot images
confirming caNrf2-induced upregulation of HO-1 and SRXN1 at the protein level
in CPCs compared to mCherry-transduced cells. For each group in A, n = 4. Bar
graphs show mean ± SEM. *, p < 0.05.
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oxidoreductase 1 (NQO1) [78], glutamate-cystein ligase catalytic (GCL-C),
glutamate-cystein ligase modifier (GCL-M), GSH reductase (GSR), and SRXN1
(See Fig. 9A). Western blot analyses were also performed and corroborated the
induction of HO-1 and SRXN1 at the protein level (Fig. 9B). These observations
support that overexpressed caNrf2 bound to the promoter regions of target genes
and upregulated the transcription of Nrf2 target genes.
caNrf2 overexpression protects CPCs against oxidative stress
After demonstrating the ability of caNrf2 to upregulate antioxidant genes, the
ability of caNrf2 overexpression to protect CPCs from oxidative stress conditions
was examined. To that end, 1.0 x 104 mCherry- and caNrf2-overexpressing
CPCs were plated onto a 96-well plate and then cultured using regular 10% FBScontaining F12 medium. Next day, medium was replaced with regular F12
medium containing the redox cycling agent DMNQ at a concentration of 25 μM to
induce oxidative stress before assessing cell viability. Indeed, significant
protection was observed in caNrf2-overexpressing cells at 24 and 48 hours postDMNQ treatment, as assessed by the Prestoblue cell viability assay (Fig. 10A).
Next, caNrf2-expressing CPCs were subjected to a combination of DMNQ and
serum-deprivation. To achieve that, regular CPC medium was replaced with
serum-free F12 medium containing 12 μM DMNQ. caNrf2 overexpression,
protected CPCs that are exposed to DMNQ and serum starvation at both 48 and
72 hours following DMNQ treatment (Fig. 10B), confirming the protective role of
caNrf2 overexpression in CPCs.
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Figure 10. caNrf2 overexpression protects CPCs against oxidative stress.
A, CPCs transduced with mCherry- or caNrf2-encoding lentivirus were subjected
to 25 μM DMNQ in regular CPC complete medium (A) or to 12 μM DMNQ in
serum-free medium (B). Prestoblue viability assay was performed at the
indicated time points. For each group, n = 4. Bar graphs show mean ± SEM. *, p
< 0.05.
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To monitor viability of caNrf2-overexpressing CPCs at multiple time points, rather
than taking a snap shot at 1 or 2 time points, a time-course analysis was
performed by assessing viability at regular intervals. Twenty four hours after
plating cells, 25 μM DMNQ was freshly added to the culturing medium and was
renewed daily. Prestoblue assay was performed every 12 hours. Our results
show that caNrf2 overexpression resulted in a significant protection in caNrf2expressing CPCs starting at 24 hours and up to 60 hours post DMNQ treatment
(Fig. 11A). Following that, the ability of caNrf2 to promote cell survival of CPCs
was assessed upon exposure to a different source of oxidative stress. This time,
caNrf2-expressing cells were incubated with 1.5 mM H2O2 prior to the cell
viability assessment. As expected, caNrf2 gene delivery improved cell resistance
to H2O2-induced toxicity at the time points analyzed (1, 2, 3, 4, 5 and 6 hours
following H2O2 treatment) (Fig. 11B). Taken together, these data show a
significant survival advantage of caNrf2-expressing CPCs under oxidative stress.
Finally, to exclude any caNrf2-mediated impact on proliferation, mCherry- and
caNrf2-overexpressing CPCs were seeded at a low density and proliferation was
monitored at 12-hour intervals. Our data show that caNrf2-expressing CPCs
proliferated in a manner comparable to mCherry-transduced cells (Fig. 12).
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Figure 11. Time-course cell viability analysis for caNrf2- and mCherryoverexpressing CPCs under oxidative stress. CPCs transduced with
mCherry- or caNrf2-encoding lentivirus, were subjected to 25 μM DMNQ (upper
panel) or to 1.5 mM H2O2 (lower panel). Prestoblue viability assay were
performed at the indicated time points. The data indicate that caNrf2
overexpression protects CPCs from oxidative stress. For each time point, n = 4.
Data are shown as mean ± SEM. *, p < 0.05.
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Figure 12. Effect of caNrf2 overexpression on CPC proliferation under
normal conditions. Five thousand CPCs transduced with mCherry- or caNrf2encoding lentivirus were plated in a 96-well plate in regular complete medium. To
assess proliferation, relative cell number at 12 hour intervals for 4 days was
determined using the Prestoblue viability assay. No significant difference was
noted between mCherry- and caNrf2-overexpressing CPCs at all the time points
analyzed. For each time point, n = 4. Data are shown as mean ± SEM.
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Discussion
It is accepted that the mammalian myocardium has very limited
regenerative capacity after injury [79]. Thus, introducing exogenous cells that
have the ability to regenerate or repair the heart constitutes a conceivable
approach to treat MI-induced heart failure. To that end, several cell types have
already been investigated, including cardiomyocytes [80], skeletal myoblasts
[81], MSCs, [29] CPCs [9] or even smooth muscle cells [82] and fibroblasts [83].
Among these cell types, cardiomyocytes are theoretically the ideal candidate to
replace lost cardiomyocytes. However, providing a reliable source of human
cardiomyocytes remains unresolved. Thus, stem cells which have the ability to
proliferate robustly and generate functional progeny provide an alternative to
cardiomyocytes for heart cell replacement therapies.
Among stem cells that can be utilized for cardiac repair, CPCs offer a
number of advantages. Unlike other types of stem cells, findings from
independent laboratories have validated the ability of CPCs to generate not only
cardiomyocytes, but also other cell types present in the cardiac tissue such as
smooth muscle cells and endothelial cells [9, 35, 84]. Also, use of CPCs have not
been associated with adverse side effects or oncogenic transformations,
conferring them a significant safety advantage over the use of embryonic stem
cells and induced pluripotent stem cells [85]. Indeed, these encouraging results
observed with CPC grafting in animal models were conducive to the initiation of a
phase I clinical trial, which corroborated both the safety and the therapeutic
potential of CPCs [19].
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Nevertheless, one of the remaining challenges for CPC-based therapy is
that the majority of infused cells do not survive in the host tissue. For instance,
our group has previously shown that ~99% of transplanted CPCs were
undetected in the heart at 35 days post implantation [21, 22]. Thus, strategies
that can enhance CPC survival after adoptive transfer are needed. To that end, a
number of strategies have been utilized, including exposure to hypoxic
preconditioning [86], chemical activation of HO-1 [36], delivery of growth factors
genes [87], prosurvival genes and heat shock treatment [34]. In this study, we
demonstrate for the first time in CPCs, that caNrf2 overexpression enhances the
CPC resistance to oxidative stress. Our data show that caNrf2 protected CPCs
against the redox cycler DMNQ with and without serum deprivation (Fig. 10 and
11). Furthermore, caNrf2 protected CPCs against another oxidative stress
inducer, H2O2 (Fig. 11).
In line with our findings, previous studies have shown the beneficial effect
of Nrf2 activation. For instance, sulforaphane (a Nrf2 activator) has been shown
to upregulate Nqo1 and to protect astrocytes from oxidative stress [71]. Also,
Nrf2 activation through selective deletion of Keap1 in Clara cells in the mouse
lung upregulated the expression of Nqo1 and Gcl-m, and that was accompanied
by a protection against oxidative stress ex vivo and boosted the resistance of
lungs against cigarette smoke-induced inflammation [88]. In intact animals,
boosting Nrf2 activity with pharmacological agents was also protective against
oxidative damage [89]. More importantly, Nrf2 has also been shown to play a
significant role in stem cell survival and function. For instance, hematopoietic
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stem progenitor cells (HPSCs) from Nrf2-knockout mice had significantly higher
rates of spontaneous apoptosis and had lower survival rates when exposed to
oxidative stress [68]. The study also showed that Nrf2 is indispensable for
myeloid development and stem cell function of HPSCs. Collectively, these lines
of evidence, along with our findings, support a beneficial outcome of Nrf2
activation, which may be utilized to advance cell-based cardiac repair.
It is possible that caNrf2 overexpression in CPCs may affect their
proliferation. For instance, Schafer et al. found that overexpressing caNrf2 in
mice had a negative effect on keratinocyte proliferation [90]. In the present study,
however, caNrf2 overexpression had no effect on the proliferation rate of CPCs
under normal unstressed conditions (Fig. 12). These data suggest that caNrf2induced effect on proliferation is cell-specific and that caNrf2-overxepressing
CPCs retain their normal proliferative potential. This also indicates that the role
caNrf2 plays in CPCs is protecting them against oxidative stress, rather than
promoting their proliferation.
The cytoprotective effects of Nrf2 activation is thought to be mediated
through a battery of antioxidant genes such as GCL, GSR, NQO1, HO-1, and
SRXN1. These proteins play important roles in cellular responses to oxidative
stress and thus help protect cells from oxidative stress [66]. Consistent with that,
our findings show that caNrf2 overexpression in CPCs was associated with
transcriptional induction of several Nrf2 target genes including GCL-C, GCL-M,
GSR, NQO1, HO-1, and SRXN1 (Fig. 9). The qRT-PCR analysis revealed that
the synthesizing components of GSH: GCL-C and GCL-M were significantly
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upregulated (Fig. 9). GCL mediates the rate limiting step of GSH synthesis. This
step involves the ATP-dependent condensation of cysteine and glutamate to
form the dipeptide gamma-glutamylcysteine (γ-GC) [91]. Structurally, GCL is
comprised of a 73 kDa heavy catalytic subunit (GCL-c) and a 31 kDa light
modifier subunit (GCL-m) and genes encoding the two subunits have been
shown to contain ARE sequences at their promoters [91]. Several studies have
shown the transcriptional and functional association between Nrf2 and GSH, and
the role of GSH in combating oxidative stress. For instance, Nrf2-knockout mice
have been shown to express lower levels of GSH [92]. Also, N-acetyl L-cysteine
(NAC), a precursor of GSH, was effective in protecting cells against Fasmediated toxicity [93]. In addition to GCL, the GSH- replenishing enzyme GSR is
also needed for GSH homeostasis and cellular activity. When GSH is oxidized,
GSR is responsible for reducing the GSH oxidized form (GSSG) to the sulfhydryl
form (GSH), to maintain a healthy reducing environment within the cell [94, 95].
Similar to what was observed with the GCL subunits, our data show a significant
induction of GSR mRNA levels in caNrf2-overexpressing CPCs (Fig. 9).
In addition to the transcriptional elevation of enzymes that restore GSH
levels, caNrf2 induced transcription of other Nrf2 target genes, most notably HO1 and SRXN1 (Fig. 9). HO-1 is the inducible form of HO and is transcriptionally
regulated by Nrf2 whereas HO-2 is the constitutive form. Both HO-1 and HO-2
mediate heme (pro-oxidant) breakdown, to produce biliverdin (an antioxidant that
can be converted to bilirubin by biliverdin reductase) and carbon monoxide (an
antioxidant exclusively synthesized by HO-1) [96, 97]. Previous studies have
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shown the role of Nrf2 in upregulating HO-1 transcripts and the importance of the
latter in ameliorating ROS damage. For instance, conditional expression of a Nrf2
dominant-negative mutant was accompanied by 85-95% reduction in the HO-1
transcript

in

response

to

heme,

cadmium,

zinc,

arsenite,

and

tert-

butylhydroquinone [98], supporting that HO-1 is one of the principal target genes
of Nrf2. In addition, chemical activation of HO-1 through cobalt protoporphyrin
was beneficial to CPCs by promoting ERK/Nrf2 signaling, and conferring
protection against oxidative stress [36]. In accordance with that, our results show
~30 fold induction in the HO-1 mRNA transcript in caNrf2-expressing CPCs (Fig.
9), corroborating the association between Nrf2 activation and HO-1 expression.
Another target gene of Nrf2-activation is SRXN1 which is believed to lower
oxidative stress by re-activating peroxiredoxins (a family of peroxidases) that are
inhibited by over-oxidation [99]. Our qRT-PCR revealed that caNrf2-expressing
CPCs had a ~20 fold higher transcript level of SRXN1 (Fig. 9). Although not
tested, it is possible that that both HO-1 and SRXN1 play major roles in
mediating caNrf2 protective effect in CPCs.
Like other Nrf2 target genes, mutational studies have identified the
presence of ARE sequence in the promotor region of NQO1 [100]. NQO1 is a
prototypical Nrf2 target gene that catalyzes the reduction and detoxification of
highly reactive redox cycling quinones that can cause cellular damage [76].
Several studies have shown that Nrf2 activation promotes Nqo1 expression,
which in turn help promote cell survival. For instance, Nrf2 activation by Keap1
selective deletion in the mouse lung was associated with increased levels of
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Nqo1 [88]. When a pharmacological inhibitor of NQO1 was added, the cells were
sensitized to Fas ligand-induced apoptosis [93], indicating a prosurvival role of
NQO1. In line with these studies, there was a small but significant induction of
NQO1 mRNA levels in caNrf2-overexpresing CPCs (Fig. 9).
Although this study did not look at the mechanisms by which caNrf2
promotes CPC viability under oxidative stress conditions, Nrf2 has been reported
to possess multiple beneficial effects. 1) Nrf2 directly decreases oxidative stress
by influencing homeostasis of ROS and reactive nitrogen species (RNS) [67]. For
instance, Nrf2 promotes catabolism of superoxide and peroxides by increasing
the cellular levels of superoxide dismutase (SOD), GSH peroxidase and
peroxiredoxin. Nrf2 also promotes synthesis of reducing factors such as GSH
and NADPH, and replenishes oxidized cofactors and proteins (including oxidized
GSH) by upregulating the transcription of specific reductases [67, 101]. 2) Nrf2
activation has been shown to inhibit apoptosis [101, 102] although the precise
mechanisms by which this occurs remain to be elucidated. Indeed, when Nrf2
was inhibited in HeLa cells by expressing an antisense Nrf2 cDNA or a
membrane permeable dominant-negative polypeptide, the cells were sensitized
to Fas-induced apoptosis and that was rescued by Nrf2 overexpression [93]. 3)
Nrf2 induces the expression of a class of proteosomal proteins, and thus reduces
protein aggregation that is detrimental to cells [103]. In support of that,
sulforaphane protected murine neuroblastoma cells from amyloid beta (Aβ)
aggregation-induced toxicity [104]. 4) Studies have revealed a beneficial antiinflammatory effect for Nrf2. For instance, Nrf2 can attenuate NFkappaB-
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inflammatory response in vitro and in vivo [105]. Also, inducing expression of
Nrf2 in microglia by using the phenolic antioxidant tBHQ, prevented LPS-induced
microglial hyperactivation and attenuated overproduction of pro-inflammatory
neurotoxic mediators like TNF-α, IL-1β, IL-6, prostaglandin E2 (PGE2), and nitric
oxide (NO) [106]. Based on these reports, we speculate that in addition to caNrf2
ability to protect CPCs from oxidative stress, it may confer additional benefits to
CPC survival by one or more of the following mechanisms: inhibiting apoptosis,
reducing protein aggregation and/or reducing inflammatory mediators.
In summary, our data show that caNrf2 can protect CPCs against
oxidative stress conditions in vitro with no apparent impact on cell proliferation.
However, despite these promising results observed with caNrf2-expressing
CPCs, it is important to be cautious when interpreting these data since all the
experiments in this work were performed only under in vitro conditions.
Therefore, whether caNrf2-overexpression in CPCs would be protective in vivo
needs further investigation. It would be particularly interesting to test the
prosurvival role of caNrf2 in cells upon implantation in an animal model of MI. If
proved effective, caNrf2 gene delivery may have significant implications for MIinduced heart failure.
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CHAPTER IV
SUMMARY
MI-induced heart failure presents a major challenge because none of the
existing therapies are capable of reversing myocardial death. Fortunately, newer
approaches including CPC-based therapies are promising venues because they
offer a potential to modify the underlying pathophysiology, either by replacing
dead cells and/or by protecting the remaining ones. Indeed, this relatively new
CPC field is advancing fast and is achieving encouraging results, albeit with a
few unresolved concerns.
Among these concerns, poor survivability of transplants and their inability
to generate functional cardiac cell types, hinder further advancement of the cellbased heart repair. It is thus imperative that more investigations be carried out to
understand and resolve these issues. The present work focused on genetically
engineering CPCs to facilitate their differentiation into committed cardiac lineages
and to confer cells better protection against oxidative stress. The data indicate
that Gata4 and caNrf2 gene delivery have the potential to address CPC poor
differentiation and survival, respectively. Gata4 overexpression was able to direct
the differentiation of CPCs into 3 out of the 4 main cardiac cell lineages
(cardiomyocytes,

smooth

muscle

cells

and

fibroblasts).

Combining

a

differentiation medium (5% FBS-containing DMEM) and dexamethasone with
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Gata4 overexpression shifted the differentiation into only the cardiomyocyte
lineage. Determining the therapeutic advantage, if any, of CPCs committed to
multiple cardiac cell lineages, versus those committed to cardiomyocytes only,
need

further

investigation.

With

regard

to

promoting

CPC

survival,

overexpressing caNrf2, which has the ability to activate several antioxidants and
phase II detoxifying enzymes, protected CPCs against multiple oxidative stress
conditions in vitro with no impact on cell proliferation.
Because the experiments performed in this work were performed under in
vitro conditions, it would be interesting to confirm these findings by assessing
whether

Gata4-,

caNrf2-

or

Gata4-caNrf2-overexpressing

CPCs

are

therapeutically superior to naïve CPCs in an appropriate animal model of MI.
Such studies need to analyze not only the differentiation and survivability of
implanted cells in the infarcted heart, but also the ability of cells to result in
improved cardiac function. Success of these genetically-engineered CPCs in vivo
may have implications not only for ischemic cardiomyopathy but also in other
diseases that may benefit from cell-based therapies.
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flow cytometry, confocal microscopy and lentivirus transduction.
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